GlassScriptPhysician profile
Melissa Johnston
NPI 1700160231
$6,142.60
in general payments reported to CMS, 2019-2025
20 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.74 · 2022: $1,034 · 2023: $1,862 · 2024: $1,965 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,038 · Education: $57.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,038.21 |
| Education | $57.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,754.54 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $932.19 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $799.88 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $466.54 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $424.25 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $329.90 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $278.68 | 2022-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $266.70 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $178.68 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $162.72 | 2023-2025 | Rexulti |
| Abbott Laboratories | $133.85 | 2024 | Proclaim |
| Alkermes, INC. | $110.73 | 2024-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $99.16 | 2022-2025 | Trintellix |
| Corium, LLC | $80.39 | 2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $37.31 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $23.79 | 2025 | Fanapt, Hetlioz |
| Harmony Biosciences LLC | $20.84 | 2022 | |
| Novo Nordisk INC | $16.60 | 2023 | Wegovy |
| Indivior INC. | $13.11 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.